Remimazolam Tosilate + Propofol

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

General Anesthesia

Conditions

General Anesthesia

Trial Timeline

Dec 1, 2014 → Aug 1, 2015

NCT ID

NCT02406872

About Remimazolam Tosilate + Propofol

Remimazolam Tosilate + Propofol is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for General Anesthesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02406872. Target conditions include General Anesthesia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04400201	Phase 3	Completed	Jun 15, 2020	Oct 30, 2020	Sedation
NCT03921775	Phase 3	Completed	May 13, 2019	Dec 30, 2019	Anesthesia for Elective Surgery Patients
NCT03779061	Phase 3	Completed	Jun 28, 2018	Sep 28, 2018	Sedation
NCT03425474	Phase 3	Completed	Sep 1, 2017	Nov 10, 2017	Sedation
NCT03003884	Phase 2	Completed	Nov 1, 2016	Mar 1, 2017	Sedation
NCT02406872	Phase 2	Completed	Dec 1, 2014	Aug 1, 2015	General Anesthesia

Competing Products

20 competing products in General Anesthesia

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	65
Satralizumab	Chugai Pharmaceutical	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Perampanel + Placebo comparator	Eisai	Phase 3	77
zonisamide	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Perampanel	Eisai	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Cenobamate	Ono Pharmaceutical	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Approved	85
Ixekizumab	Eli Lilly	Approved	85
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	52
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	85
Remimazolam Tosilate for Injection	Jiangsu Hengrui Medicine	Pre-clinical	23
HR020602 injection + fentanyl injection ； remifentanil injection	Jiangsu Hengrui Medicine	Phase 2	52
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	52
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	52
ABBV-932 + Placebo	AbbVie	Phase 1	33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved